For more information regarding recent media reports about SINGULAIR, please see below:

• FDA Early Communication About an Ongoing Safety Review of Montelukast (SINGULAIR)
• Merck Statement on the FDA Early Communication of an Ongoing Safety Review of Montelukast (SINGULAIR)

• Patient Information for SINGULAIR and Prescribing Information for SINGULAIR in English
• Patient Information for SINGULAIR and Prescribing Information for SINGULAIR in Spanish

SINGULAIR is a prescription medicine approved to help control symptoms of asthma in adults and children 12 months and older and for relief of symptoms of indoor and outdoor allergies (outdoor allergies in adults and children as young as 2 years and indoor allergies in adults and children as young as 6 months).

IMPORTANT SAFETY INFORMATION

SINGULAIR will not replace fast-acting inhalers for sudden symptoms. Continue to take your other asthma medicines as prescribed and have fast-acting medication available. For asthma, SINGULAIR should be taken once a day, in the evening as prescribed, whether or not you have asthma symptoms. If your symptoms get worse or you need to increase the use of your rescue inhaler, call your doctor at once.

Side effects are generally mild and vary by age, and may include headache, ear infection, sore throat, and upper respiratory infection. Check with your doctor if you are pregnant or nursing. SINGULAIR should be taken once a day, as prescribed. SINGULAIR is available by prescription only.

SINGULAIR has not been studied as a treatment option for both conditions in the same person.